Clinical Trial Update: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body [Phase 2]

View source ↗

Summary

Phase 2 study to evaluate REGN7999 for iron overload in adults with non-transfusion-dependent beta-thalassemia; the trial is currently recruiting and uses MRI t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-transfusion-dependent Beta-thalassemia

Drugs mentioned

• REGN7999

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT) | Phase 2 | Status: RECRUITING